Aura Biosciences, Inc.
US ˙ NasdaqGM ˙ US05153U1079

SecurityAURA / Aura Biosciences, Inc.
InstitutionBlackRock, Inc.
Latest Disclosed Ownership3,336,027 shares
Ownership 5.40%
BlackRock, Inc. ownership in AURA / Aura Biosciences, Inc.

2025-10-17 - BlackRock, Inc. has filed an SCHEDULE 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 3,336,027 shares of Aura Biosciences, Inc. (US:AURA). This represents 5.4 percent ownership of the company. In their previous filing dated 2025-07-16 , BlackRock, Inc. had reported owning 3,037,923 shares, indicating an increase of 9.81 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2025-10-17 2025-10-17 13G 3,037,923 3,336,027 9.81 5.40 10.20
2025-07-16 2025-07-16 13G/A 3,160,414 3,037,923 -3.88 4.90 -23.44
2024-11-08 2024-11-08 13G 3,160,414 3,160,414 0.00 6.40 0.00
2024-10-22 2024-10-22 13G 3,160,414 6.40

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F AURA BIOSCIENCES COM 05153U107 3,586,640 26,216 0.74 23,995 23.65 0.0000
2026-02-12 2025-12-31 13F AURA BIOSCIENCES COM 05153U107 3,560,424 154,947 4.55 19,404 -7.80 0.0003
2025-11-12 2025-09-30 13F AURA BIOSCIENCES COM 05153U107 3,405,477 302,953 9.76 21,046 8.36 0.0004
2025-08-12 2025-06-30 13F AURA BIOSCIENCES COM 05153U107 3,102,524 -437,424 -12.36 19,422 -6.38 0.0004
2025-05-02 2025-03-31 13F AURA BIOSCIENCES COM 05153U107 3,539,948 -11,509 -0.32 20,744 -28.94 0.0004
2025-02-07 2024-12-31 13F AURA BIOSCIENCES COM 05153U107 3,551,457 391,043 12.37 29,193 3.67 0.0006
2024-11-13 2024-09-30 13F AURA BIOSCIENCES COM 05153U107 3,160,414 155,052 5.16 28,159 23.94 0.0006
2024-08-13 2024-06-30 13F AURA BIOSCIENCES COM 05153U107 3,005,362 560,521 22.93 22,721 18.38 0.0005
2024-05-10 2024-03-31 13F AURA BIOSCIENCES COM 05153U107 2,444,841 346,096 16.49 19,192 3.22 0.0004
2024-02-13 2023-12-31 13F AURA BIOSCIENCES COM 05153U107 2,098,745 234,719 12.59 18,595 11.21 0.0005
2023-11-13 2023-09-30 13F AURA BIOSCIENCES COM 05153U107 1,864,026 -8,106 -0.43 16,720 -27.68 0.0005
2023-08-11 2023-06-30 13F AURA BIOSCIENCES COM 05153U107 1,872,132 541,032 40.65 23,121 87.18 0.0006
2023-05-12 2023-03-31 13F AURA BIOSCIENCES COM 05153U107 1,331,100 277,973 26.40 12,353 11.71 0.0004
2023-02-13 2022-12-31 13F AURA BIOSCIENCES COM 05153U107 1,053,127 39,672 3.91 11,058 -39.79 0.0003
2022-11-14 2022-09-30 13F AURA BIOSCIENCES COM 05153U107 1,013,455 126,732 14.29 18,363 46.13 0.0006
2022-08-12 2022-06-30 13F AURA BIOSCIENCES COM 05153U107 886,723 611,696 222.41 12,566 107.70 0.0004
2022-05-12 2022-03-31 13F AURA BIOSCIENCES COM 05153U107 275,027 36,244 15.18 6,050 49.20 0.0002
2022-02-10 2021-12-31 13F AURA BIOSCIENCES COM 05153U107 238,783 238,783 4,055 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.